Tekmira's LNP Technology Enables Alnylam's Positive ALN-TTR02 Clinical Data
July 16, 2012 11:12 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, July 16, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira's LNP Technology Enables ALN-VSP Clinical Data
June 04, 2012 10:36 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 4, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
May 24, 2012 18:13 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 24, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a...
Tekmira Provides Corporate Update and Announces First Quarter 2012 Results
May 15, 2012 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 15, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira's LNP Technology Enables Alnylam's ALN-TTR01 Clinical Data
May 10, 2012 09:56 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 10, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter 2012 Results
May 09, 2012 16:47 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data
April 20, 2012 10:51 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 20, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Provides Corporate Update and Announces 2011 Results
March 27, 2012 16:01 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
March 26, 2012 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 26, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2011 Audited Results
March 22, 2012 16:40 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 22, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...